An innovative treatment for acute
herpetic keratitis (dendritic ulcers)
Effectively
and Precisely
Target Virally
Infected Cells
ZIRG
Imp
is indicated for top
®
RGAN
portant Risk Informatio
pical ophthalmic use only. P
®
on for ZIRGAN
. Patients should not wear co
ontact lenses if they have si
igns or symptoms
li
Zirga
For pr
Ple
blur
of he
d by B h & L b I d
is a trademark of Laboratoires Théa C
®
n
roduct-related questions or concerns, cal
ase see brief summary o
rred vision (60%), eye irrita
f herpetic keratitis or during t
orporation
www.bau or visit 1-800-323-0000 l
y of the full prescribing inf
ation (20%), punctate kera
g the course of therapy with Z
. usch.com
®
formation for ZIRGAN
atitis (5%), and conjunctiva
. Most commo
®
h ZIRGAN
on adjacent page.
®
al hyperemia (5%).
n adverse reactions report
ted in patients were
© 20
licens
010 Bausch & Lomb Incorporated. Printed i
sed by Bausch & Lomb Incorporated.
d in USA PH3467 10/10
